

# Shared Decision Making for Financial Advocates

ACCC Financial Advocacy Network Summit

August 16, 2018

Downtown Washington DC





# ACCC Shared Decision Making for Financial Advocates Summit - August 2018, Washington DC

# Navigating Medicare and Medicaid

Dan Sherman, MA, LPC
The NaVectis Group



## Medicaid

#### ·In 2016,

- 72.2 million Americans were enrolled in Medicaid.
- 19.4% of our population.
- 43% of this population are children.
- 10.2 Million Americans are dual eligible.
- 20% of Medicare beneficiaries are enrolled in Medicaid.



- 50% of Medicare beneficiaries fall below 200% of FPL. KFF, 2014
- 1/3 of Medicare patients on Gleevec failed to fill prescriptions within 6 months of diagnosis due to cost. Journal of Clinical Oncology, 2016.
- Medicare patients with cancer spend an average of 11% of their income on treatment. JAMA Oncology, 2016
- Patients who don't have supplemental insurance spend 23% of their income on cancer care. Jama Oncology, 2016
- The probability of experiencing OOP burden of at least 20% of income is 75% higher for Medicare oncology patients compared to Medicare beneficiaries without cancer. Cancer 2012



- Medicare part A
- Medicare part B
- Medicare part C
- Medicare part D
- Medigap A, B, C, D, F, G, K, L, M, N
- MAPD plans
- Medicare Savings Program (QMB, SLMB, QI)
- Low Income Subsidy








# Knowledge Base

- Essential to have knowledge of basic concepts and programs
  - MSP, QMB, SLMB, QI, LIS, MAPD, PD, Medigap A, B, C, D, F, G, K, L, M, N, Medicare Part A, B, C, D, HMO, PPO, SNP...
  - Understanding Medicaid enrollment guidelines
    - Medicaid Expansion Program
    - Disability Medicaid
    - Caregiver Medicaid
    - QMB
    - ESO Medicaid
  - Need expert knowledge of these programs in order to apply them to the appropriate patient at the appropriate time.



11% of Medicare beneficiaries have Medicare A/B only KFF 2014





## Scenarios

- Transitioning from Medicaid Expansion to Medicare
- Medicaid Expansion and SSDI payments vs. SSI payments
- Utilizing LIS and MSP with Medicare Beneficiaries
- How do you navigate Medicare A/B only patients
- Navigating Marketplace or COBRA policies for Medicare eligible patients
- Navigating SSDI Medicare beneficiaries
  - Supplemental vs. MAPD
  - Turning 65

•



## **Shared Decision Making**

What if we focus our attention on taking a proactive approach on....

educating patients on the Medicaid and Medicare system?



- Medicare A and B only
  - Medicaid
  - Medigap
  - MAPD
  - MSP
  - LIS
  - 5 Star Rule



#### Case Study: April 2018

71-year-old married male diagnosis with stage IV colon cancer. Monthly household gross income is \$1,590 and they have \$10,000 in assets. He has Medicare A, B and D only.

Treatment regimen included surgery followed by bevacizumab, Oxaliplatin (twice monthly) and oral capecitabine for 12 months, along with anti-nausea and pain medications. He will also need palliative radiation treatments. He is struggling to afford his oral medications.

Total treatment cost for one year estimated to be around \$350,000

Patient responsibility estimated to be around \$40,000



#### **Optimizing Insurance Coverage**

- o LIS
- Medicare intervention (Medigap vs. MAPD)

#### **Optimizing External Assistance Programs**

- o PAN \$7,500
- o MSP \$2,900

Estimated Savings to the Patient \$43,000

Estimated Savings to the Provider \$40,000



# Medicare part D

Medicare part D

Initial coverage


\$3,750

Coverage Gap

\$5,000

- 65% discount (Brand)
- 56% discount (Generic)
- 85% counted toward CG

• Cat. coverage 5%





## Medicare part D

- LIS
  - Level 1-4
  - No open enrollment for:
    - Part D
    - MAPD plan

Walgreens #15466

Rite Aid Pharmacy 01519

**Mail Order Pharmacy** 

Walgreens #15466 - Preferred Retail Cost Sharing

			Drug Costs During Coverage Levels		
SELECTED DRUGS	FULL COST OF DRUG	Refill Frequency	Initial Coverage Level[?]	Coverage Gap[?]	Catastrophic Coverage[?]
Fentanyl Transdermal DIS 50MCG/HR	\$52.70	Every 1 Month	\$23.19	\$23.19	\$3.35
Imbruvica CAP 140MG	\$14,360.98	Every 1 Month	\$4,739.12	\$5,026.34	\$718.05
Lantus Solostar INJ SOLOSTAR	\$383.22	Every 1 Month	\$42.00	\$134.13	\$19.16
Ondansetron ODT TAB 8MG ODT	\$7.15	Every 1 Month	\$7.00	\$3.15	\$3.35
Zolpidem Tartrate Er TAB 6.25MG	\$88.20	Every 1 Month	\$38.81	\$38.81	\$4.41
MONTHLY TOTALS:	\$14,892.25		\$4,850.12	\$5,225.62	\$748.32



Estimated Monthly Drug Costs

Walgreens #15466

Rite Aid Pharmacy 01519

**Mail Order Pharmacy** 

Monthly Costs for the Rest of the Year (based on enrollment today)

N/A #2.002 #021 #021 #021 #021 #021 #021

ተ021

ተርጋ1

Walgreens #15466

#### Rite Aid Pharmacy 01519

#### **Mail Order Pharmacy**

Walgreens #15466 - Preferred Retail Cost Sharing (Cost includes extra help)

			Drug Costs During Coverage Levels		
SELECTED DRUGS	FULL COST OF DRUG	Refill Frequency	Initial Coverage Period	Post-Initial Coverage Period	Catastrophic[?]
Fentanyl Transdermal DIS 50MCG/HR	\$52.70	Every 1 Month	\$3.35	\$3.35	\$0.00
Imbruvica CAP 140MG	\$14,360.98	Every 1 Month	\$8.35	\$8.35	\$0.00
Lantus Solostar INJ SOLOSTAR	\$383.22	Every 1 Month	\$8.35	\$8.35	\$0.00
Ondansetron ODT TAB 8MG ODT	\$7.15	Every 1 Month	\$3.35	\$3.35	\$0.00
Zolpidem Tartrate Er TAB 6.25MG	\$88.20	Every 1 Month	\$3.35	\$3.35	\$0.00
MONTHLY TOTALS:	\$14,892.25		\$26.75	\$26.75	\$0.00



**Estimated Monthly Drug Costs** 

Walgreens #15466

Rite Aid Pharmacy 01519

**Mail Order Pharmacy** 



## **Screening Patients**

- Does patient distress screening work?
- Focus on specific patient populations:
  - Medicare only
  - New to Medicare patients
  - COBRA & Marketplace patients who become eligible for Medicare
  - Medicare beneficiaries with no part D coverage
  - Medicare beneficiaries on high dollar oral oncolytic treatments
  - Medicaid patients who are approved for SSDI
  - Medicaid patients who become eligible for Medicare



#### Discussion Questions

- Who has responsibility to address these issues?
- Is it realistic to have financial counselors provide this type of education?
- Should there be certification requirements for the role?



#### Thank You!

Dan Sherman, MA, LPC Founder and President
The NaVectis Group



